NasdaqGS:TXMD

Stock Analysis Report

Executive Summary

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States.


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has TherapeuticsMD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TXMD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.8%

TXMD

9.9%

US Pharmaceuticals

12.5%

US Market


1 Year Return

-77.6%

TXMD

-12.4%

US Pharmaceuticals

-12.7%

US Market

Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned -12.4% over the past year.

Return vs Market: TXMD underperformed the US Market which returned -12.7% over the past year.


Shareholder returns

TXMDIndustryMarket
7 Day10.8%9.9%12.5%
30 Day-36.1%-8.4%-14.7%
90 Day-55.4%-16.9%-21.5%
1 Year-77.6%-77.6%-10.1%-12.4%-10.9%-12.7%
3 Year-85.4%-85.4%6.7%-1.0%12.6%5.4%
5 Year-82.8%-82.8%10.5%-1.7%31.9%17.5%

Price Volatility Vs. Market

How volatile is TherapeuticsMD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TherapeuticsMD undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TXMD ($1.08) is trading below our estimate of fair value ($14.85)

Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TXMD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: TXMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TXMD is overvalued based on its PB Ratio (31.8x) compared to the US Pharmaceuticals industry average (2.4x).


Next Steps

Future Growth

How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

62.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: TXMD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TXMD's is expected to become profitable in the next 3 years.

Revenue vs Market: TXMD's revenue (37.6% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: TXMD's revenue (37.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TherapeuticsMD performed over the past 5 years?

-19.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TXMD is currently unprofitable.

Growing Profit Margin: TXMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of -19% per year.

Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).


Return on Equity

High ROE: TXMD has a negative Return on Equity (-1914.39%), as it is currently unprofitable.


Next Steps

Financial Health

How is TherapeuticsMD's financial position?


Financial Position Analysis

Short Term Liabilities: TXMD's short term assets ($208.4M) exceed its short term liabilities ($53.0M).

Long Term Liabilities: TXMD's short term assets ($208.4M) exceed its long term liabilities ($203.8M).


Debt to Equity History and Analysis

Debt Level: TXMD's debt to equity ratio (2115.3%) is considered high.

Reducing Debt: Insufficient data to determine if TXMD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TXMD has a low level of unsold assets or inventory.

Debt Coverage by Assets: TXMD's debt is covered by short term assets (assets are 1.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TXMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -25.4% each year.


Next Steps

Dividend

What is TherapeuticsMD's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TXMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

Rob Finizio (48yo)

8.42s

Tenure

Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio serves as Director of ZyVersa Therapeutics, I ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD1.49M).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Finizio
Co-Founder8.42yrsno data7.49% $22.0m
John C. Milligan
President8.42yrsno data2.05% $6.0m
Brian Bernick
Co-Founderno dataUS$1.21m2.45% $7.2m
Daniel Cartwright
CFO & Treasurer8.42yrsno datano data
Mitchell Krassan
Executive VP and Chief Strategy & Performance Officer8.42yrsno datano data
Michael Donegan
Vice President of Finance6.92yrsno datano data
Jason Spitz
Vice President of Commercial Development & Operationsno datano datano data
Joel Krasnow
Chief Scientific Officer and Head of Regulatory Department6.25yrsno datano data
Adam Miller
Chief Information Officer2yrsno datano data
Nichol Ochsner
Vice President of Investor Relations2.17yrsno datano data

7.7yrs

Average Tenure

52yo

Average Age

Experienced Management: TXMD's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Finizio
Co-Founder8.42yrsno data7.49% $22.0m
Gail Naughton
Independent Directorno datano datano data
Paul Bisaro
Independent Directorno datano datano data
Angus Russell
Independent Director5yrsUS$256.29k0.034% $101.0k
J. Carroll
Independent Director5yrsUS$260.79k0.0037% $10.8k
Thomas Thompson
Independent Chairman of the Board7.83yrsUS$378.31k0.26% $751.1k
Cooper Collins
Independent Director8yrsUS$272.54k0.024% $71.3k
Jules Müsing
Independent Director6.83yrsUS$245.04k0.0018% $5.4k
Robert LaPenta
Independent Director8yrsUS$275.04k0.0037% $10.8k
Jane Barlow
Independent Director2yrsUS$247.29k0.0012% $3.4k

7.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: TXMD's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

TherapeuticsMD, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TherapeuticsMD, Inc.
  • Ticker: TXMD
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$293.248m
  • Shares outstanding: 271.53m
  • Website: https://www.therapeuticsmd.com

Number of Employees


Location

  • TherapeuticsMD, Inc.
  • 951 Yamato Road
  • Suite 220
  • Boca Raton
  • Florida
  • 33431
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TXMDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2011
29TDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011
29TBRSE (Berne Stock Exchange)YesCommon StockCHCHFOct 2011

Biography

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company’s clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 04:14
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.